[1] CHELLIAN R, PANDY V, MOHAMED Z. Biphasic Effects of α-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity[J]. Front Pharmacol,2016,7:72. [2] HAJ-MIRZAIAN A, KORDJAZY N, AMIRI S. Involvement of nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tropisetron and ondansetron in mice forced swimming test and tail suspension test[J]. Eur J Pharmacol, 2016,780(5):71-81. [3] POLESZAK E, SZOPA A, WYSKA E.Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim andtail suspension tests in mice[J]. Pharmacol Rep, 2016,68(1):56-61. [4] YAN S, YOU ZL, ZHAO QY.Antidepressant-like effects of Sanyuansan in the mouse forced swim test, tail suspension test, and chronic mild stress model[J]. Kaohsiung J Med Sci, 2015;31(12):605-612. [5] KORDJAZY N, HAJ-MIRZAIAN A, AMIRI S. Involvement of N-methyl-d-aspartate receptors in the antidepressant-like effect of 5-hydroxytryptamine 3 antagonists in mouse forced swimming test and tail suspension test[J]. Pharmacol Biochem Behav,2016,141:1-9. [6] PINTO BROD LM, FRONZA MG, VARGAS JP. Involvement of monoaminergic system in the antidepressant-like effect of (octylseleno)-xylofuranoside in the mouse tail suspension test[J]. Prog Neuropsychopharmacol Biol Psychiatry,2016,65:201-207. [7] ABOU-ELNAGA AF, TORIGOE D, FOUDA MM, et al. Identification of multiple genetic loci in the mouse controlling immobility time in the tail suspensionand forced swimming tests[J]. Jpn J Vet Res, 2015, 63(2):53-62. [8] CHRISTOPHER J. YUSKAITIS, MARJELO A,et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndrome[J]. Biochem Pharmacology, 2010,79(4):632-646. [9] PRESCOTT TL, HAYES J, PRIDE M, et al. Normal performance of fmr1 mice on a touchscreen delayed nonmatching to position working memory task[J/OL]. eNeuro,2016,3(1).[2016-04-25] http://europepmc.org/articles/PMC4800045.DOI:10.1523/ENEURO.0143-15.2016. [10] MARKO UUTELA, JESSE LINDHOLM, TOMIRANTAMÄKI, et al. Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome[J]. Cell Neurosci,2014,8: 150. [11] THOMAS AM, BUI N, GRAHAM D, et al. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome[J]. Behav Brain Res, 2011,223(2): 310-321. |